The global gout therapeutics market is estimated to reach USD 9.82 billion by 2026 growing at a CAGR of 15.2% from 2019 to 2026. Gout is a common and intricate form of arthritis that can affect any human being. Gout is in general characterized by the intense joint pain, persistent discomfort, joint inflammation, and redness. Moreover, as gout progresses the movement of joints get restricted and size of base of big toe is increased.
Gout is majorly influenced due to accumulation urate crystals in the joint which in turn can cause inflammation and intense pain of gout attack. These urate crystals are caused due to presence of high level of uric acid in the blood. The uric acid in the blood plays an important role in breaking down purines in the body. Purines are majorly found in some food items such as steak, organ meats and seafood, beer, and various other drinks that are sweetened with fruit sugar. In general, the uric acid dissolves in the blood and the body expels it out through urination. The major risk factors that influence gout in an individual are changing eating habits, and obesity.
Know more about this report: request for sample pages
The growth in this market is largely driven by the rise in population suffering from gout across the globe. This increased prevalence is observed due to the changing lifestyle which has resulted in increased alcohol consumption, increasing consumption of purine diet, rising obesity, and various kidney related disorders. In addition, consumption of biologic drugs such as Rilonacept, Krystexxa, and Canakinumab is expected to increase as these are already introduced in the market. These biologics have the capability to produce strong anti-inflammatory action that has driven the demand for this therapy in the market. Also, multiple other drugs are in the clinical trials phase which are eventually expected to be launched and introduced in the market enabling further growth in gout therapeutics industry. Therefore, increasing awareness about the availability of these therapies in the global market, has encouraged investment across various research and development activities by the existing manufacturers and also the governments.
By Drug Class
By Disease Condition
Know more about this report: request for sample pages
The market research report on gout therapeutics is segmented on the basis of drug type, disease condition, and geography. On the basis drug type, the gout therapeutics market is segmented as urate-lowering agents, corticosteroids, nonsteroidal anti-inflammatory drugs [NSAIDs], and colchicine. Non-steroidal anti-inflammatory drugs (NSAIDs) was observed to be the dominant drug type in this market during 2018. Usage of NSAIDs is popular due to its ease of availability than other drugs. In addition, its cost effectiveness as compared to other drugs in the market is another factor supporting the growth of this drug class during the forecast period.
While, the urate-lowering agents drug type is projected to grow at a faster rate among all the covered drug types. These agents are characterized majorly by the existence of xanthine oxidase inhibitor and uricosuric agents. Introduction of various drugs and growing preference towards adoption of this treatment is also expected to drive the growth in this industry.
Based on the disease condition, the gout therapeutics market is segmented as acute gout, and chronic gout. Chronic gout segment dominated the market during 2018, and is expected to maintain this position, as this segment uses urate-lowering agents. Similarly, acute gout is majorly treated with the various NSAID’s and other options.
By geography, the market report on gout therapeutics covers analysis of five major regions, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America region dominates the gout therapeutics market across all regions. The growth in the North America regional market is driven by the continuous increase in number of patients suffering from gout, and relatively high number of key manufacturers present in this region. Moreover, rising awareness for treating gout with the help of therapies, and continuous research and development activities focusing on innovating new urate-lowering agents. The Asia-Pacific regional market is expected to grow at a faster rate owing to the continuous increase in the investments by the key players, increasing number of patients, along with rising preference for the use of gout treatment therapies. Furthermore, high number of smoking population in this region, and increasing alcohol consumption due to changing lifestyle are other factors which influence higher occurrence of gout among patients and is expected to boost the adoption of gout therapeutics.
The increase in demand for effective gout drugs enabling successful therapies has resulted in more R&D spending by the companies in this industry. Also, there is a trend of undertaking various strategic initiatives including acquisitions, mergers, and collaboration. For instance, Horizon Pharma plc acquired Crealta Holdings LLC in 2015 enabling the company to diversify its medicine offerings portfolio. As a part of this acquisition KRYSTEXXA was added to the Horizon Pharma’s portfolio; KRYSTEXXA is FDA approved medicine for the therapy of chronic refractory gout.
Some of the key and prominent vendors operating in the global gout therapeutics market includes AstraZeneca (UK), Horizon Pharma plc (Ireland), Takeda Pharmaceutical Company Limited (Japan), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Merck & Co. Inc. (U.S.), Teijin Pharma Limited (Japan), Regeneron Pharmaceuticals, Inc. (U.S.), Ironwood Pharmaceuticals, Inc. (U.S.), JW Pharmaceutical (South Korea), Selecta Biosciences, Inc. (U.S.), Grunenthal Group (Germany).